Rebound-associated vertebral fractures after denosumab discontinuation in a lung cancer patient with bone metastases

Denosumab is a commonly used antiresorptive treatment in patients with osteoporosis or solid tumours with bone metastases. Upon denosumab discontinuation, a rebound phenomenon can occur that results in an increased (vertebral) fracture risk. This phenomenon is well-known in the setting of osteoporos...

Descripción completa

Detalles Bibliográficos
Autores principales: Dupont, Jolan, Appermans, Wesley, Dejaeger, Marian, Wauters, Isabelle, Laurent, Michaël R., Gielen, Evelien
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9109183/
https://www.ncbi.nlm.nih.gov/pubmed/35585959
http://dx.doi.org/10.1016/j.bonr.2022.101582
_version_ 1784708852274429952
author Dupont, Jolan
Appermans, Wesley
Dejaeger, Marian
Wauters, Isabelle
Laurent, Michaël R.
Gielen, Evelien
author_facet Dupont, Jolan
Appermans, Wesley
Dejaeger, Marian
Wauters, Isabelle
Laurent, Michaël R.
Gielen, Evelien
author_sort Dupont, Jolan
collection PubMed
description Denosumab is a commonly used antiresorptive treatment in patients with osteoporosis or solid tumours with bone metastases. Upon denosumab discontinuation, a rebound phenomenon can occur that results in an increased (vertebral) fracture risk. This phenomenon is well-known in the setting of osteoporosis but rarely reported in cancer patients with bone metastases discontinuing denosumab. We present the case of a 43-year old women with lung cancer and bone metastases who suffered multiple vertebral fractures after discontinuation of denosumab.
format Online
Article
Text
id pubmed-9109183
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-91091832022-05-17 Rebound-associated vertebral fractures after denosumab discontinuation in a lung cancer patient with bone metastases Dupont, Jolan Appermans, Wesley Dejaeger, Marian Wauters, Isabelle Laurent, Michaël R. Gielen, Evelien Bone Rep Case Report Denosumab is a commonly used antiresorptive treatment in patients with osteoporosis or solid tumours with bone metastases. Upon denosumab discontinuation, a rebound phenomenon can occur that results in an increased (vertebral) fracture risk. This phenomenon is well-known in the setting of osteoporosis but rarely reported in cancer patients with bone metastases discontinuing denosumab. We present the case of a 43-year old women with lung cancer and bone metastases who suffered multiple vertebral fractures after discontinuation of denosumab. Elsevier 2022-05-04 /pmc/articles/PMC9109183/ /pubmed/35585959 http://dx.doi.org/10.1016/j.bonr.2022.101582 Text en © 2022 The Authors https://creativecommons.org/licenses/by/4.0/This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Case Report
Dupont, Jolan
Appermans, Wesley
Dejaeger, Marian
Wauters, Isabelle
Laurent, Michaël R.
Gielen, Evelien
Rebound-associated vertebral fractures after denosumab discontinuation in a lung cancer patient with bone metastases
title Rebound-associated vertebral fractures after denosumab discontinuation in a lung cancer patient with bone metastases
title_full Rebound-associated vertebral fractures after denosumab discontinuation in a lung cancer patient with bone metastases
title_fullStr Rebound-associated vertebral fractures after denosumab discontinuation in a lung cancer patient with bone metastases
title_full_unstemmed Rebound-associated vertebral fractures after denosumab discontinuation in a lung cancer patient with bone metastases
title_short Rebound-associated vertebral fractures after denosumab discontinuation in a lung cancer patient with bone metastases
title_sort rebound-associated vertebral fractures after denosumab discontinuation in a lung cancer patient with bone metastases
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9109183/
https://www.ncbi.nlm.nih.gov/pubmed/35585959
http://dx.doi.org/10.1016/j.bonr.2022.101582
work_keys_str_mv AT dupontjolan reboundassociatedvertebralfracturesafterdenosumabdiscontinuationinalungcancerpatientwithbonemetastases
AT appermanswesley reboundassociatedvertebralfracturesafterdenosumabdiscontinuationinalungcancerpatientwithbonemetastases
AT dejaegermarian reboundassociatedvertebralfracturesafterdenosumabdiscontinuationinalungcancerpatientwithbonemetastases
AT wautersisabelle reboundassociatedvertebralfracturesafterdenosumabdiscontinuationinalungcancerpatientwithbonemetastases
AT laurentmichaelr reboundassociatedvertebralfracturesafterdenosumabdiscontinuationinalungcancerpatientwithbonemetastases
AT gielenevelien reboundassociatedvertebralfracturesafterdenosumabdiscontinuationinalungcancerpatientwithbonemetastases

Ejemplares similares